Globus Medical (GMED) vs Solventum (SOLV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Solventum (SOLV) has outperformed Globus Medical (GMED) over the past year, gaining 1.9% versus a loss of 22.2%. Solventum is the larger company by market cap ($14.36 billion vs $8.86 billion), about 1.6 times the size, while Globus Medical is growing revenue faster (+16.7% vs +0.9%). On valuation, Solventum trades at a lower forward P/E (11.2x vs 12.5x for Globus Medical).
Solventum converts more of its revenue into profit, with a net margin of 18.7% versus 18.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMED | SOLV |
|---|---|---|
| Share price | $66.89 | $84.50 |
| Market cap | $8.86B | $14.36B |
| 1-day change | -2.49% | -1.52% |
| YTD return | -23.39% | +6.64% |
| 1-year return | -22.24% | +1.93% |
| 5-year return | +4.60% | — |
| P/E ratio (TTM) | 16.48 | 94.94 |
| Forward P/E | 12.53 | 11.20 |
| EPS (TTM) | $4.06 | $0.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.94B | $8.32B |
| Revenue growth (YoY) | +16.65% | +0.86% |
| Net income (latest FY) | $537.87M | $1.56B |
| Gross margin | 67.41% | 53.47% |
| Operating margin | 16.33% | 26.20% |
| Net margin | 18.30% | 18.69% |
| 52-week high | $101.40 | $94.16 |
| 52-week low | $66.63 | $62.38 |
| Distance from 52-week high | -34.03% | -10.26% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +39.68% | +16.43% |
| Average volume | 1.63M | 1.03M |
| Shares outstanding | 110.04M | 169.96M |
| Employees | 6,000 | 20,584 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SOLV has outperformed GMED by 24.2 percentage points over the past year.
- Solventum trades at a higher earnings multiple (94.9x vs 16.5x trailing P/E).
- Globus Medical grew revenue faster in its latest fiscal year (+16.65% vs +0.86%).
About Globus Medical
GMED stock →Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.
Health Care · Medical/Dental Instruments · 6,000 employees
About Solventum
SOLV stock →Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems.
Health Care · Medical/Dental Instruments · 20,584 employees
GMED vs SOLV FAQ
Which is bigger, Globus Medical or Solventum?
Solventum (SOLV) is larger, with a market capitalization of $14.36B compared with $8.86B for Globus Medical (GMED).
Which stock has performed better over the past year, GMED or SOLV?
SOLV returned +1.93% over the past 12 months, compared with -22.24% for GMED (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GMED or SOLV?
GMED has the lower trailing P/E at 16.5, versus 94.9 for SOLV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Globus Medical and Solventum in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.